Establishing meaningful dialogue
19th Aug 2011
The time has come for the industry to reconsider its approach to communicating with patients
In the early 1980s, patient activism took the UK by storm and forever changed the way pharma interacted with the end users of its products. Thirty years on, it's not just the patient advocacy groups demanding a greater voice; Parliament is calling on individual patients to drive improvements in the quality and efficiency of healthcare provision. Industry must find new ways to engage with less visible patients at a grass roots level.
In this Op-Ed for Pharmaceutical Market Europe, Cohn & Wolfe's Global Healthcare Practice Leader, Mike Kan, addresses discusses a new, more effective way for the pharmaceutical industry to communicate with 'real world' patients.
